{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-089595","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2025-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.775134+00:00","generated_at":"2026-05-17T06:07:26.314962+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Longeveron enters $10.7M ATM equity offering with H.C. Wainwright","bullets":["Up to $10.7M of Class A common stock may be sold at market prices through agent Wainwright.","Commission 3.0% of gross proceeds; company reimburses up to $100k legal fees plus periodic diligence fees.","Net proceeds to fund clinical development of laromestrocel for HLHS, Alzheimer's, and pediatric DCM.","No minimum sales obligation; company or Wainwright may suspend the offering at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-089595","json":"https://secwatch.observer/filing/0001213900-25-089595.json","markdown":"https://secwatch.observer/filing/0001213900-25-089595.md","text":"https://secwatch.observer/filing/0001213900-25-089595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025089595/0001213900-25-089595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025089595/ea0257855-8k_long.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:07:26.314962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}